Monte Rosa Therapeutics Inc (GLUE) Stock Analysis

Monte Rosa Therapeutics Inc (GLUE) is a publicly traded company in the HEALTHCARE sector. It trades at $17.74, carries a market capitalization of $1.67B. This page summarizes the public market data, fundamentals, and frequently asked questions for GLUE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Monte Rosa Therapeutics Inc currently has a Neutral sentiment score of 0.07.

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc. (GLUE) is a cutting-edge biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing precision small molecule therapeutics that exploit the body’s innate mechanisms for targeted protein degradation. The company's proprietary technology platforms enable it to tackle significant unmet medical needs in various fields, particularly in cancer and autoimmune disorders. With a promising pipeline of candidates and a strong commitment to scie...

GNG Research Analysis

GNG Research scores Monte Rosa Therapeutics Inc (GLUE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GLUE.

Frequently Asked Questions

Does GLUE pay dividends?

Monte Rosa Therapeutics Inc (GLUE) does not currently pay a regular dividend.

What is GLUE's market cap?

Monte Rosa Therapeutics Inc (GLUE) has a market capitalization of $1.67B with a current stock price of $17.74.